Abbvie announces 100% SVR12 response in Turquoise-111 Phase 3b study results
coolheat said
Jun 25, 2015
That is so wonderful!!!! Clouds are opening up, gold light is pouring through.....
Cinnamon Girl said
Jun 25, 2015
NORTH CHICAGO, Ill., June 24,2015
AbbVie today announced TURQUOISE-III study results demonstrating 100 percent (n=60/60) sustained virologic response at 12 weeks post-treatment (SVR12) in genotype 1b chronic hepatitis C virus infected adult patients with compensated liver cirrhosis.
Patients received 12 weeks of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets) without ribavirin. These new results from AbbVie's Phase 3b study will be presented at the 15th Annual International Symposium on Viral Hepatitis and Liver Diseases in Berlin, Germany.
NORTH CHICAGO, Ill., June 24,2015
AbbVie today announced TURQUOISE-III study results demonstrating 100 percent (n=60/60) sustained virologic response at 12 weeks post-treatment (SVR12) in genotype 1b chronic hepatitis C virus infected adult patients with compensated liver cirrhosis.
Patients received 12 weeks of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets) without ribavirin. These new results from AbbVie's Phase 3b study will be presented at the 15th Annual International Symposium on Viral Hepatitis and Liver Diseases in Berlin, Germany.
Full details...
http://hcvadvocate.blogspot.ca/2015/06/abbvie-announces-new-phase-3b-results.html